Rhythm Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 week.
- Recent price momentum is +7.4% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 17.0% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 89.7% | Better than 96% |
| Operating margin | -101.2% | Better than 7% |
| Net margin | -106.4% | Better than 7% |
| Return on equity | -251.1% | Better than 2% |
| Return on invested capital | -233.8% | Better than 1% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 2.1% | Better than 79% |
| 6-month return | 27.9% | Better than 88% |
| 12-month return (ex latest month) | -12.3% | Better than 21% |
| Distance below 52-week high | 8.1% | Better than 88% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.4x | Better than 83% |
| Debt to assets | 0.8% | Better than 93% |
| Interest coverage | -8.5x | Better than 14% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 93.3% | Better than 76% |
| Upside to average target | 33.2% | Better than 52% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 116.80
- Open
- 115.46
- Day range
- 112.00 - 117.01
- Avg price
- 113.86
- Volume
- 1.50M
- Turnover
- 171.09M
- Turnover ratei
- 2.66%
- Volume ratioi
- 0.95
- Amplitudei
- 4.29%
- 52-week rangei
- 74.50 - 122.20
Valuation
- P/Ei
- -36.13
- P/E (TTM)i
- -38.61
- P/Bi
- 88.54
- EPSi
- -3.11
- Book value / shi
- 1.27
- Net profit
- -215.62M
- Net assets
- 87.98M
Share structure
- Market cap
- 7.79B
- Float capi
- 6.35B
- Shares out
- 69.33M
- Float sharesi
- 56.52M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2017-10-05
8.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+7.62M net over the window
Short interest
- Shares short
- 11.68M
- % of floati
- 16.96%
- Days to coveri
- 23.33
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Rhythm Pharmaceuticals (RYTM)?
Rhythm Pharmaceuticals last traded at 112.36. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Rhythm Pharmaceuticals's market cap?
About 7.79B.
What is the P/E ratio of Rhythm Pharmaceuticals?
The trailing twelve-month P/E is -38.61. The Valuation tab shows it against the stock's own five-year range.
Does Rhythm Pharmaceuticals pay a dividend?
Rhythm Pharmaceuticals does not currently pay a regular dividend.
Is Rhythm Pharmaceuticals a buy according to analysts?
The consensus of 15 analysts is a Buy rating, with an average 12-month price target of 149.64, which implies 33.2% upside from the current price. This is not investment advice.
What is Rhythm Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Rhythm Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Rhythm Pharmaceuticals discussion 0 comments